The OPRK1 antibody targets the κ-Opioid Receptor, a G-protein coupled receptor (GPCR) expressed in the brain and peripheral tissues. It binds endogenous ligands (e.g., dynorphins) and synthetic opioids, modulating pain perception, anxiety, and addiction pathways . The HRP conjugation enables enzymatic amplification of target detection via chromogenic substrates (e.g., TMB, DAB), enhancing assay sensitivity .
Detects OPRK1 protein in lysates from brain, spinal cord, or peripheral tissues .
Example: A study using a polyclonal OPRK1 antibody (unconjugated) identified two isoforms (33 kDa/42 kDa) in rat brain lysates .
Localizes OPRK1 in brain regions like the hypothalamus and amygdala .
HRP-conjugated antibodies are compatible with chromogenic detection (e.g., DAB staining) .
OPRK1-expressing neurons in the basolateral amygdala (BLA) regulate anxiety-like behaviors. Chemogenetic activation of BLA KORs reduced anxiety in female mice without altering nociceptive thresholds .
Hypothalamic OPRK1 interacts with ghrelin receptors to modulate orexigenic responses. Silencing OPRK1 in the arcuate nucleus (ARC) attenuated ghrelin-induced feeding .
Variants in the OPRK1 gene correlate with alcohol dependence and opioid addiction. HRP-conjugated antibodies could aid in identifying receptor changes in addiction models .